undamentalytics Newsletter
Sign in

Abbott Laboratories (ABT) stock

Add to watchlist

Add holding +

NYSE: ABT NYSE Health Care Equipment Next results ~January 21, 2027

B Fundamentals grade

Abbott Laboratories discovers, develops, manufactures and sells healthcare products. It makes branded generic medicines such as Creon, Synthroid and the Influvac flu vaccine; diagnostic instruments and tests under names including Alinity, ARCHITECT, i-STAT and the BinaxNOW rapid tests; nutritional products including the Similac infant formulas, Ensure, PediaSure and Glucerna; and medical devices for cardiovascular care (including MitraClip and the XIENCE stent), the FreeStyle Libre glucose monitor and neuromodulation devices for chronic pain.

It earns revenue by selling these goods. Depending on the segment, customers include wholesalers, distributors, hospitals, clinics, laboratories, blood banks, pharmacies, retailers, government agencies and, for nutrition, consumers directly. Products are shipped from Abbott-owned distribution centres, public warehouses or third-party distributors.

The business is organised into four reportable segments: Established Pharmaceutical Products (sold outside the United States in emerging markets), Diagnostic Products, Nutritional Products and Medical Devices. Abbott sells worldwide and employed about 115,000 people at the end of 2025, 69% of them outside the US, operating in more than 160 countries. An Illinois corporation incorporated in 1900, it agreed in November 2025 to acquire Exact Sciences to enter cancer diagnostics.

Based on Abbott Laboratories's 10-K filed February 20, 2026.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

~$73

Cash-flow model

Base case. Range ~$51–$100 across our lower- and higher-growth cases (1.5%–11.5% a year).

Price vs value

Overvalued

The price is above our entire value range; our base value is 34% below it.

Price used: $110.16, November 2, 2026

Abbott Laboratories valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

Value diary

Our note on each quarter Abbott Laboratories files

Where Abbott Laboratories stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $46.6bn, up 8.1% on a year earlier, faster than 6.6% a quarter earlier. Free-cash-flow margin rose to 16.8% from 15.7% a year earlier. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 3 of our 6 financial-health checks. Our cash-flow model value is $66.22 a share, against a share price of $103. At that price, our model says the market is pricing in about 13.2% a year of cash-flow growth for five years, faster than the 1.6% a year revenue growth it has delivered.

Source: 10-Q filed July 28, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~January 21, 2027 (estimated)

Abbott Laboratories's trailing-twelve-month revenue grew 8.1% year on year, with a free-cash-flow margin of 16.8%. Where it stands out: free-cash-flow margin of 16.8% ranks 17 of 128 health care equipment companies we cover.

Our discounted-cash-flow model values the business at ~$73 per share in the base case (~$51–$100 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 15.5% while net income fell 61.2%: a 77pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Abbott Laboratories's latest figures clears our strength thresholds.

Things to watch

  • Priced above our value. The share price of $110.16 is 34% above our value per share of $73.

Latest results: FY2026 Q2

Filed July 28, 2026
Earnings per share
$1.42 against an average estimate of $1.42: beat by 0.0%
Revenue
$12.59bn, up 13.0% on a year earlier
Share reaction
+0.1% in the first session after the results on October 21, 2026, against -0.7% for the S&P 500
Guidance given
comparable sales growth growth 6% (full-year 2026); adjusted diluted earnings per share $5.5 to $5.55 (full-year 2026)
Next report
October 21, 2026; average EPS estimate $1.64

Abbott Laboratories' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+3.7%
  • 1 week+5.0%
  • 1 month+13.7%
  • This year-9.9%
  • 1 year-8.7%
  • 5 years-5.4%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$46.6B
Operating margin
15.8%
Net margin
11.6%
EPS (TTM, diluted)
$3.11

Growth

Revenue growth
+8.1%
Change in growth rate
+1.5 pts
Share count change
−0.1%

Cash

Free cash flow (TTM)
$7.8B
FCF margin
16.8%
Stock pay % of revenue
1.5%

Earnings

Last results
October 21, 2026
Next results (est.)
January 21, 2027

News & updates

Updated November 2, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Results

    Abbott reports third-quarter 2026 results

    Abbott Laboratories said it announced its third-quarter 2026 results on October 21, 2026. The company filed an 8-K with the SEC, including a press release that presents non-GAAP financial measures. These figures exclude items such as acquisition costs and intangible amortization to show ongoing performance.

    SEC 8-KRead source ↗
  3. Guidance
  4. Insider trade
  5. Announcement
  6. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Abbott Laboratories valuation models and calculator

What the price is pricing in

The share price implies about 13.2% a year of cash-flow growth for five years.That is faster than the 1.6% a year revenue growth Abbott Laboratories has delivered.

  • Priced in13.2%
  • Last 12 months8.1%
  • 3 years a year5.0%
  • 5 years a year1.6%

Our cash-flow model with every input fixed except growth over the next five years, solved for the growth at which the model value equals the share price ($109.22, Nov 3, 2026). Cash-flow growth then fades to 2.5% a year; discount rate 8.5%. Delivered figures are revenue growth from SEC filings. This is a model exercise, not investment advice or a forecast of the share price. All companies

Fundamentalytics rating

model v1.6 · 2026-11-03
Sell12-month view
12-month price target
~$73
Price used
$109.22close November 3, 2026
Implied change
▼ 33%
Uncertainty
Medium

How we got here: a discounted-cash-flow model of Abbott Laboratories's free cash flow after stock-based pay with after-tax interest added back ($7B, FY2026 Q2 TTM), growing 9.7% and 6.8% in the next two years (forecasts, guidance and its record), then back to 6.5% by year five, and fading to 2.5%, discounted at 8.5%. Lower and higher growth cases span ~$51–~$100 ; that spread sets a 25% margin before we rate Buy or Sell.

Produced by Fundamentalytics' automated valuation model on November 3, 2026, using delayed market prices. Rating meanings, methodology and conflicts: recommendations disclosure and research disclaimer. General research, not personal advice — it does not consider your circumstances. Prices can fall as well as rise.

Our value per share comes from a discounted-cash-flow model of Abbott Laboratories's free cash flow after stock-based pay ( $7B, FY2026 Q2 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

Valuation models

We value Abbott Laboratories as an operating company, with every model that fits that kind of business. Cost of equity 8%: the 10-year Treasury yield (4.9%) plus a beta of 0.68 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$73 ~$51–$100 Primary model, counts double
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$98 ~$86–$160 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$81 ~$60–$110 Included
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$93 ~$78–$120 Included
Combined value Weighted average of the models that apply: the primary model (cash-flow model (dcf)) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$84 ~$73–$98 4 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Abbott Laboratories with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

What moves the value

  • Revenue growth 5 points lower ▼ −29%
  • Revenue growth 5 points higher ▲ +38%
  • Free-cash-flow margin 1 point lower ▼ −6%
  • Last year's free-cash-flow margin change, if it persists ▲ +8%
  • Discount rate 1 point higher ▼ −18%
Value per share under different assumptions
Discount rate ↓ / growth → −5% growth0% growth5% growth10% growth15% growth20% growth
7% $41$62$90$126$174$235
8.5% $28$43$63$89$123$166
10% $20$31$47$66$92$125

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$36.30$31.83$48.38$62.44$76.23$97.61$127.41$101.06$103.34$108.31$122.25$110.16
Market value$54.7bn$47.2bn$84.6bn$110.5bn$135.8bn$174.3bn$227.9bn$178.3bn$180.7bn$189.3bn$213.7bn$192.3bn
+ Net debt (− = net cash)$4.0bn$3.4bn$18.5bn$15.7bn$14.3bn$11.9bn$8.3bn$6.9bn$7.8bn$6.5bn$4.4bn$27.5bn
Enterprise value$58.7bn$50.6bn$103.1bn$126.2bn$150.0bn$186.2bn$236.2bn$185.2bn$188.5bn$195.8bn$218.1bn$219.8bn
Multiples
Price / sales 2.7x2.3x3.1x3.6x4.3x5.0x5.3x4.1x4.5x4.5x4.8x4.1x
Price / earnings 12.4x33.7x177.4x46.7x36.8x38.8x32.2x25.7x31.6x14.1x32.8x35.5x
Price / free cash flow 29.5x22.7x19.1x22.5x30.2x30.5x26.4x22.8x35.7x29.8x28.9x24.6x
EV / EBITDA 15.7x13.2x39.5x26.6x26.7x28.4x23.8x19.3x24.3x24.0x23.0x24.8x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

72 /100

Strong moat

How hard Abbott Laboratories's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 8 / 20

    Net income has been a median 6.0% of total assets over 10 years.

  • Pricing power 18 / 20

    Gross margin has been a median 55.5%, moving by 2.9 percentage points (standard deviation) across 10 years.

  • Durability 11 / 20

    Operating margin has been a median 15.5%; its worst year was 7.8%.

  • Cash conversion 18 / 20

    Free cash flow was positive in 10 of 10 years, at a median 15.1% of revenue.

  • Discipline 18 / 20

    The diluted share count fell 2.5% over five years; stock-based pay has been a median 1.5% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $5.52 +7% $50.0bn +13%
Next $5.94 +8% $53.5bn +7%

Next year's EPS estimate has moved −2.1% in 90 days, across 27 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +0.0% on 90 days ago. In the last 30 days, 1 analyst raised Abbott Laboratories's forecast and 2 cut it.

Consensus EPS forecast Abbott Laboratories, last 90 days
$5.40 $5.60 $5.80 $6.00 $6.20 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $5.52 Current fiscal year, 60 days ago: $5.52 Current fiscal year, 30 days ago: $5.52 Current fiscal year, 7 days ago: $5.52 Current fiscal year, Now: $5.52 $5.52 Next fiscal year, 90 days ago: $6.06 Next fiscal year, 60 days ago: $6.06 Next fiscal year, 30 days ago: $6.07 Next fiscal year, 7 days ago: $6.07 Next fiscal year, Now: $5.94 $5.94

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $5.52$6.06
60 days ago $5.52$6.06
30 days ago $5.52$6.07
7 days ago $5.52$6.07
Now $5.52$5.94

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2026 $1.42 $1.42 0.0%
Jun 2026 $1.28 $1.31 +2.6%
Mar 2026 $1.15 $1.15 +0.3%
Dec 2025 $1.49 $1.50 +0.3%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, October 21, 2026
  • comparable sales growth full-year 2026 about 6% growth Non-GAAP
    “Abbott projects full-year 2026 comparable sales growth to be approximately 6.0% 1 .” source
  • adjusted diluted earnings per share full-year 2026 $5.50 to $5.55 Non-GAAP Narrowed
    “Abbott reaffirms the midpoint of previously provided full-year 2026 adjusted diluted EPS guidance range and tightens the range to $5.50 to $5.55.” source
  • adjusted diluted earnings per share fourth-quarter 2026 $1.62 to $1.67 Non-GAAP
    “Abbott projects fourth-quarter 2026 adjusted diluted earnings per share of $1.62 to $1.67.” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

How our valuation uses these forecasts

Our cash-flow model grows Abbott Laboratories's revenue by +9.7% next year and +6.8% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (+11.1%, weight 70%) and the company's own record (+6.5%, weight 30%) . How the weights are set.

Analyst recommendations

28 analysts, Oct 2026
Buy2382%
Hold518%
Sell00%

Monthly trend

  1. Oct 2026518528
  2. Sep 2026418527
  3. Aug 2026417627
  4. Jul 2026416727

Counts of recommendations published by analysts covering Abbott Laboratories, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
1.1%
of tradable shares
Days to cover
1.84
at average volume
Short interest, 1 month
−13%
to October 15, 2026
Held by institutions
82%
of shares
Held by insiders
0.5%
of shares
Employees
122,000
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −8.7%

$120.62 on October 31, 2025 to $110.16

ThenNowEffect
Revenue (last 12 months) $43.1bn $46.6bn +8.1%
Net margin 32.4% 11.6% −64.1%
P/E multiple 15.1x 35.5x +135.2%
Share count 1747m 1746m +0.1%

Biggest factor: net margin.

Last 3 years +22.4%

$89.98 on November 3, 2023 to $110.16

ThenNowEffect
Revenue (last 12 months) $40.2bn $46.6bn +15.8%
Net margin 12.8% 11.6% −9.2%
P/E multiple 30.6x 35.5x +15.9%
Share count 1754m 1746m +0.5%

Biggest factor: p/e multiple.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
ABT+31%−21%+2%+5%+13%−10%
Industry peers (median)−9%−37%−9%−20%−16%−15%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
ABT58%42%50%58%58%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
ABT−17%−31%−21%−16%−13%−35%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 40% from March 3, 2025 to May 11, 2026. Getting back needed a 66% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$81.47 – $127.42
From 52-week high
−13.5%
vs 50-day average
+6.2%
vs 200-day average
+9.7%
Volatility (1 year)
28%
Beta vs S&P 500
-0.03

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
5 up, 7 down
typical move ±4.7%
After a week
6 up, 6 down
typical move ±4.9%
After a month
5 up, 6 down
typical move ±7.9%
Results releasedNext dayS&P 500 next day5 days21 days
October 21, 2026 +0.1% −0.7% +0.2% —
July 16, 2026 +12.8% −1.5% +12.9% +24.6%
April 16, 2026 −4.7% +1.5% −8.9% −16.8%
January 22, 2026 −11.0% +0.6% −12.1% −4.5%
October 15, 2025 −3.8% −0.2% −3.6% −2.6%
July 17, 2025 −6.1% +0.5% −4.6% 0.0%
April 16, 2025 +3.8% −2.1% +2.5% +6.8%
January 22, 2025 +5.5% +1.1% +9.5% +15.5%
October 16, 2024 +1.6% +0.4% +0.8% −0.9%
July 18, 2024 −2.5% −1.4% +1.2% +6.0%
April 17, 2024 −3.6% −0.8% −2.1% −4.0%
January 24, 2024 −1.4% +0.7% −0.7% +4.8%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Options strategies

All options ideas

How Abbott Laboratories’s listed options are priced, and three ways to use them that follow from our valuation. Quotes are delayed, read November 2, 2026. Check the live chain at your broker before trading.

Implied vs realised volatility

Options look rich

Option prices imply clearly more movement than the shares have shown. That strengthens the case for selling options.

  • Implied is 1.38× the last 60 days’ realised volatility , richer than 83% of the 229 stocks we screen today.
  • Why: implied is 1.38x 60-day realised, above 1-year realised, and in the top 20% of our coverage today.

Our rule for “rich”: implied at least 1.2× 60-day realised (beyond measurement noise), above 1-year realised (not just a calm spell), and in the top 20% of our coverage that day. Never with results inside the option’s life. These are our conventions, built on research showing option prices usually imply more movement than follows, most when the gap is wide. How we judge this.

Cash-secured put

Not offered: rated Sell.

We suggest selling a put only on well-rated companies, at a strike where the price you would pay if assigned (strike less premium) is at or below our fair value.

ABT Abbott Laboratories Grade B $109.68

Own 100 shares, sell the $115 call expiring December 4, 2026 (32 days) for $1.55 a share — $155 per contract.

Previous session · Bid $1.55, ask $2.00, quoted Mon 2 Nov, 17:13 New York time with ABT at $109.68. Option prices move with the shares: check the live chain at your broker before trading.

  • If ABT ends below $115: you keep your shares and the $155 — 1.4% extra on the position, 16.1% a year at that pace.
  • If it ends above $115: your shares are sold at $115, a total return of 6.3% including the premium — at or above our value of ~$73.
$687 $0 −$2.2k Break-even $108.13 Price $109.68 ← Our value ~$73
Profit or loss per contract at expiry, by share price (including the shares bought at today's price).
Premium
$155
Annualised
16.1%
Break-even
$108.13
Max gain
$686.62
Chance of selling
~32%

Collar

Own the shares, buy the $105 put and sell the $120 call, both expiring December 18, 2026 (46 days).

  • Net cost of $0.90 a share ($90.00 per contract of 100 shares).
  • Worst case at expiry: -5.1%, if the shares fall below $105 (-4.3% from today).
  • Best case at expiry: +8.6%, if the shares rise above $120 (+9.4%); gains beyond that go to the call buyer.

Offered because the shares trade at or above our fair value of $73.00: a way to hold on with a floor under the price, paid for by giving up upside the model does not expect. Strikes near 25-delta; the put at its ask and the call at its bid. Protection has a cost over time: research on protective puts finds they have usually lowered returns.

General research, not personal advice. Options can lose you more than you expect and are not suitable for everyone: put sellers can be made to buy shares that keep falling, call sellers give up gains above the strike, and results or news can move prices sharply. Chances shown are approximations from each option’s delta. Spreads, fees and early assignment are not modelled.

Abbott Laboratories in five measures

Fundamentals grade B
Growth Profitability Cash Balance sheet Value

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Abbott Laboratories
$38B $40B $42B $44B $46B $48B FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $40B Revenue (TTM), FY23 Q4: $40.1B Revenue (TTM), FY24 Q1: $40.3B Revenue (TTM), FY24 Q2: $40.7B Revenue (TTM), FY24 Q3: $41.2B Revenue (TTM), FY24 Q4: $42B Revenue (TTM), FY25 Q1: $42.3B Revenue (TTM), FY25 Q2: $43.1B Revenue (TTM), FY25 Q3: $43.8B Revenue (TTM), FY25 Q4: $44.3B Revenue (TTM), FY26 Q1: $45.1B Revenue (TTM), FY26 Q2: $46.6B $46.6B

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $40B
FY23 Q4 $40.1B
FY24 Q1 $40.3B
FY24 Q2 $40.7B
FY24 Q3 $41.2B
FY24 Q4 $42B
FY25 Q1 $42.3B
FY25 Q2 $43.1B
FY25 Q3 $43.8B
FY25 Q4 $44.3B
FY26 Q1 $45.1B
FY26 Q2 $46.6B
Revenue growth, TTM YoY Abbott Laboratories
-15% -10% -5% 0% 5% 10% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: -11.3% Revenue growth, TTM YoY, FY23 Q4: -8.1% Revenue growth, TTM YoY, FY24 Q1: -2.8% Revenue growth, TTM YoY, FY24 Q2: 1.2% Revenue growth, TTM YoY, FY24 Q3: 3.1% Revenue growth, TTM YoY, FY24 Q4: 4.6% Revenue growth, TTM YoY, FY25 Q1: 5.0% Revenue growth, TTM YoY, FY25 Q2: 5.9% Revenue growth, TTM YoY, FY25 Q3: 6.4% Revenue growth, TTM YoY, FY25 Q4: 5.7% Revenue growth, TTM YoY, FY26 Q1: 6.6% Revenue growth, TTM YoY, FY26 Q2: 8.1% 8.1%

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 -11.3%
FY23 Q4 -8.1%
FY24 Q1 -2.8%
FY24 Q2 1.2%
FY24 Q3 3.1%
FY24 Q4 4.6%
FY25 Q1 5.0%
FY25 Q2 5.9%
FY25 Q3 6.4%
FY25 Q4 5.7%
FY26 Q1 6.6%
FY26 Q2 8.1%
Operating margin (TTM) Abbott Laboratories
15% 16% 17% 18% 19% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: 15.0% Operating margin (TTM), FY23 Q4: 16.2% Operating margin (TTM), FY24 Q1: 15.8% Operating margin (TTM), FY24 Q2: 15.9% Operating margin (TTM), FY24 Q3: 16.2% Operating margin (TTM), FY24 Q4: 16.3% Operating margin (TTM), FY25 Q1: 16.8% Operating margin (TTM), FY25 Q2: 17.4% Operating margin (TTM), FY25 Q3: 17.6% Operating margin (TTM), FY25 Q4: 18.2% Operating margin (TTM), FY26 Q1: 17.1% Operating margin (TTM), FY26 Q2: 15.8% 15.8%

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 15.0%
FY23 Q4 16.2%
FY24 Q1 15.8%
FY24 Q2 15.9%
FY24 Q3 16.2%
FY24 Q4 16.3%
FY25 Q1 16.8%
FY25 Q2 17.4%
FY25 Q3 17.6%
FY25 Q4 18.2%
FY26 Q1 17.1%
FY26 Q2 15.8%
FCF margin (TTM) Abbott Laboratories
10% 12% 14% 16% 18% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: 11.2% FCF margin (TTM), FY23 Q4: 12.6% FCF margin (TTM), FY24 Q1: 12.2% FCF margin (TTM), FY24 Q2: 13.9% FCF margin (TTM), FY24 Q3: 15.7% FCF margin (TTM), FY24 Q4: 15.1% FCF margin (TTM), FY25 Q1: 15.7% FCF margin (TTM), FY25 Q2: 15.7% FCF margin (TTM), FY25 Q3: 15.8% FCF margin (TTM), FY25 Q4: 16.7% FCF margin (TTM), FY26 Q1: 16.3% FCF margin (TTM), FY26 Q2: 16.8% 16.8%

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 11.2%
FY23 Q4 12.6%
FY24 Q1 12.2%
FY24 Q2 13.9%
FY24 Q3 15.7%
FY24 Q4 15.1%
FY25 Q1 15.7%
FY25 Q2 15.7%
FY25 Q3 15.8%
FY25 Q4 16.7%
FY26 Q1 16.3%
FY26 Q2 16.8%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2025, from the 10-K

Each dollar Abbott Laboratories took in during FY2025, followed through to profit: what it cost to make, what went on research and running the business, and what was left after tax.

  1. Revenue $44.3B
  2. Other income $413M · 0.9%
  3. Cost of revenue $19.3B · 43.6%
  4. Gross profit $25B · 56.4%
  5. Research and development $2.9B · 6.6%
  6. Selling, general and admin $12.3B · 27.8%
  7. Other operating costs $1.7B · 3.8%
  8. Operating income $8.1B · 18.2%
  9. Income tax $1.9B · 4.4%
  10. Net income $6.5B · 14.7%

Shares of revenue. Source: Abbott Laboratories's 10-K for FY2025, as filed with the SEC. "Other" lines are what the reported lines leave unexplained. Other income is income outside operations, such as investment gains.

Financial statements

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Dec 2009 2010 Dec 2010 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 30.8 35.2 21.4 19.1 19.7 20.2 20.4 20.9 27.4 30.6 31.9 34.6 43.1 43.7 40.1 42.0 44.3 46.6
Gross profit — — — — — — — 11.8 15.0 17.9 18.7 19.6 24.5 24.5 22.1 23.2 25.0 26.4
EBITDA 7.4 7.3 3.0 2.7 3.1 3.5 3.7 3.8 2.6 4.8 5.6 6.6 9.9 9.6 7.8 8.2 9.5 8.9
Operating income 6.2 6.1 1.6 1.4 2.1 2.6 2.9 3.0 1.6 3.7 4.5 5.4 8.4 8.4 6.5 6.8 8.1 7.3
Net income 5.7 4.6 4.7 6.0 2.6 2.3 4.4 1.4 0.5 2.4 3.7 4.5 7.1 6.9 5.7 13.4 6.5 5.4
Diluted EPS $3.69 $2.96 $3.01 $3.72 $1.62 $1.49 $2.92 $0.94 $0.27 $1.33 $2.06 $2.50 $3.94 $3.91 $3.26 $7.64 $3.72 $3.11
Growth (year on year)
Revenue +4.2% +14.3% −39.1% −11.0% +3.2% +3.0% +0.8% +2.2% +31.3% +11.6% +4.3% +8.5% +24.5% +1.3% −8.1% +4.6% +5.7% +8.1%
EBITDA +10.4% −2.0% −58.5% −10.0% +12.4% +14.9% +6.3% +2.4% −31.8% +82.0% +18.1% +16.8% +51.3% −3.0% −19.4% +5.3% +16.2% −0.1%
Operating income +9.5% −2.4% −73.2% −16.5% +56.8% +21.8% +10.3% +5.5% −48.3% +133.4% +24.2% +18.2% +57.3% −0.7% −22.5% +5.4% +18.0% −2.2%
Net income +17.7% −19.5% +2.2% +26.1% −56.8% −11.3% +93.7% −68.3% −65.9% — +55.7% +21.9% +57.3% −2.0% −17.5% +134.2% −51.3% −61.2%
Diluted EPS +18.3% −19.8% +1.7% +23.6% −56.5% −8.0% +96.0% −67.8% −71.3% — +54.9% +21.4% +57.6% −0.8% −16.6% +134.4% −51.3% −61.2%
Margins
Gross margin — — — — — — — 56.4% 54.7% 58.4% 58.5% 56.6% 57.0% 56.1% 55.2% 55.4% 56.4% 56.6%
EBITDA margin 24.2% 20.7% 14.1% 14.3% 15.6% 17.4% 18.3% 18.4% 9.5% 15.5% 17.6% 18.9% 23.0% 22.0% 19.3% 19.5% 21.4% 19.0%
Operating margin 20.3% 17.3% 7.6% 7.1% 10.9% 12.8% 14.1% 14.5% 5.7% 11.9% 14.2% 15.5% 19.6% 19.2% 16.2% 16.3% 18.2% 15.8%
Net margin 18.7% 13.2% 22.1% 31.3% 13.1% 11.3% 21.7% 6.7% 1.7% 7.7% 11.6% 13.0% 16.4% 15.9% 14.3% 31.9% 14.7% 11.6%
Free-cash-flow margin 20.1% 22.0% 34.9% 39.5% 11.1% 12.8% 9.1% 10.0% 16.2% 16.0% 14.1% 16.5% 20.1% 17.9% 12.6% 15.1% 16.7% 16.8%
Cash flow
Cash from operations 7.3 8.7 9.0 9.3 3.3 3.7 3.0 3.2 5.6 6.3 6.1 7.9 10.5 9.6 7.3 8.6 9.6 9.9
Capital spending 1.1 1.0 1.5 1.8 1.1 1.1 1.1 1.1 1.1 1.4 1.6 2.2 1.9 1.8 2.2 2.2 2.2 2.1
Free cash flow 6.2 7.7 7.5 7.5 2.2 2.6 1.9 2.1 4.4 4.9 4.5 5.7 8.6 7.8 5.1 6.4 7.4 7.8
Stock-based pay 0.4 0.4 0.4 0.4 0.3 0.2 0.3 0.3 0.4 0.5 0.5 0.5 0.6 0.7 0.6 0.7 0.7 0.7
Free cash flow after stock pay 5.8 7.3 7.1 7.1 1.9 2.4 1.6 1.8 4.0 4.4 4.0 5.2 8.0 7.1 4.4 5.7 6.7 7.1
Balance sheet
Cash 8.8 3.6 6.8 10.8 3.5 4.1 5.0 18.6 9.4 3.8 3.9 6.8 9.8 9.9 6.9 7.6 8.5 5.1
Total debt 16.5 18.9 15.4 20.5 6.6 7.8 9.0 22.0 27.9 19.6 18.1 18.7 18.1 16.8 14.7 14.1 12.9 32.6
Net debt (negative = net cash) 7.6 15.3 8.6 9.7 3.1 3.8 4.0 3.4 18.5 15.7 14.3 11.9 8.3 6.9 7.8 6.5 4.4 27.5
Diluted shares 1,555m 1,556m 1,567m 1,592m 1,574m 1,527m 1,506m 1,483m 1,749m 1,770m 1,781m 1,786m 1,789m 1,764m 1,749m 1,748m 1,748m 1,746m
Returned to shareholders
Dividends 2.4 2.7 2.9 3.2 0.9 1.3 1.4 1.5 1.8 2.0 2.3 2.6 3.2 3.3 3.6 3.8 4.1 4.3
Buybacks 0.8 0.9 0.1 2.4 1.6 2.2 2.2 0.5 0.1 0.2 0.7 0.4 2.3 3.8 1.2 1.3 0.9 1.8
Total returned 3.2 3.5 3.0 5.5 2.5 3.5 3.7 2.1 2.0 2.2 3.0 3.0 5.5 7.1 4.8 5.1 5.0 6.1

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

3 of 6 checks passed · June 30, 2026
What it owns · $109.2bn
Short-term assets $24.5bnLonger-term assets $84.7bn
What it owes, and who funded it · $68.9bn
Short-term liabilities $17.8bnShareholders' equity $51.1bn
  • Short-term assets cover short-term liabilities $24.5bn of assets due within a year against $17.8bn of liabilities due within a year.
  • Short-term assets cover long-term liabilities Not assessable from the reported split. Not assessable.
  • More cash than debt $5.1bn of cash against $32.6bn of debt.
  • Debt below 40% of shareholders' equity Debt is 64% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 48% to 64% over five years.
  • A year's operating cash flow covers at least 20% of debt $9.9bn of operating cash flow against $32.6bn of debt.
  • Operating profit covers interest at least five times over Operating income of $7.3bn against $766m of interest.

From Abbott Laboratories's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2026 Q2 TTM
Buybacks (TTM)
$1.8B
Dividends (TTM)
$4.3B
Returned to shareholders
78%
of free cash flow
Buybacks, last 3 fiscal years
$3.4B
Diluted share count
−0.1%
year over year
Total shareholder yield
3.2%
dividends 2.2% + buybacks 0.9% of market value
Dividend payout ratio
79%
of net income paid out
R&D spending
6.8%
of revenue
Sales & admin spending
29.9%
of revenue
Days sales outstanding
67 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated ABT MDT SYK GEHC BSX PHG Median
Revenue, last 12 months $46.6bn $37.5bn $26.3bn $21.6bn $21.1bn $20.2bn $99m
Revenue growth, last 12 months 8.1% 9.8% 7.9% 6.9% 8.9% 3.4% 9.2%
Revenue growth, 3-year average 5.0% 6.0% 9.8% 3.9% 15.3% — 13.5%
Revenue growth, latest quarter 13.0% 13.7% 7.6% 7.2% 1.4% — 10.2%
Gross margin 56.6% 65.0% 65.3% 39.9% 69.1% 45.2% 61.2%
Operating margin 15.8% 18.1% 20.7% 13.3% 18.7% 8.0% −8.5%
Operating margin, 3-year average 16.4% 17.3% 18.5% 13.2% 17.4% 6.6% −17.9%
Net margin 11.6% 13.9% 13.8% 10.0% 16.6% 5.0% −12.0%
Cash from operations / revenue 21.3% 21.4% 20.7% 11.2% 20.1% — −1.9%
Free-cash-flow margin 16.8% 16.3% 17.4% 8.7% 15.8% — −3.9%
Free-cash-flow margin, 3-year average 15.5% 15.9% 16.2% 8.1% 16.4% — −7.0%
Stock pay / revenue 1.5% 1.3% 1.0% 0.7% 1.5% 0.8% 6.1%
Change in share count −0.1% 0.0% −0.1% −0.6% −0.9% 3.1% 4.0%

Median of all 134 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

134 health care equipment companies
Measure Company Peer median Rank
Revenue growth Growth 8.1% 9.1% 73 of 129
Change in growth rate Growth +1.5pp -0.6pp 38 of 129
Gross margin Profitability 56.6% 61.9% 74 of 123
Operating margin Profitability 15.8% -8.3% 20 of 132
Net margin Profitability 11.6% -12.0% 23 of 133
Free-cash-flow margin Cash generation 16.8% -3.4% 17 of 128
Stock pay as % of revenue Cash generation 1.5% 6.1% 23 of 123
Long-term debt as % of assets Balance sheet 27.1% 24.2% 49 of 87
Change in share count Balance sheet -0.1% 3.3% 31 of 115
Days sales outstanding Balance sheet 67 days 57 days 80 of 118

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Geography
Region Revenue Share YoY
Outside the US $27.2B 61.4% ▲ 6.1%
All Other Countries $16B 58.7% ▲ 8.1%
Germany $2.8B 10.1% ▲ 8.7%
China $1.9B 7.0% ▼ 9.7%
Switzerland $1.9B 6.9% ▲ 7.1%
India $1.9B 6.9% ▲ 3.0%
Japan $1.5B 5.4% ▲ 2.4%
United Kingdom $1.3B 4.9% ▲ 13.1%
United States $17.1B 38.6% ▲ 4.9%

From Abbott Laboratories's 10-K filed February 20, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$125B
Institutions reporting
2,957
Shares held vs prior quarter
▲ 0.1%
Positions opened / closed
147 / 277

Top buyers and sellers, Q2 2026: 1,202 institutions bought and 1,653 sold ; the biggest buyer was Charles Schwab Investment Management Inc (+14.2M shares) and the biggest seller Wellington Management Group LLP (−18.8M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $13.8B 152.6M 11.0% ▲ 4.7%
Vanguard Capital Management LLC $10.3B 113.8M 8.2% ▲ 0.7%
State Street Corp $7.3B 80.9M 5.9% ▲ 1.7%
Charles Schwab Investment Management Inc $5.4B 59.7M 4.3% ▲ 31.2%
Vanguard Portfolio Management LLC $4.4B 49.0M 3.5% ▲ 2.2%
Geode Capital Management, LLC $3.5B 39.2M 2.8% ▲ 0.2%
Capital Research Global Investors $3.3B 36.9M 2.7% ▼ 25.8%
Capital International Investors $3.1B 34.7M 2.5% ▼ 7.6%
Morgan Stanley $2.4B 26.6M 1.9% ▼ 11.6%
Norges Bank $2.1B 23.4M 1.7% —
Price T Rowe Associates Inc $2.1B 22.8M 1.6% ▲ 31.9%
Franklin Resources Inc $1.7B 18.8M 1.4% ▼ 6.1%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Abbott Laboratories's complete shareholder register. Values are as reported by the filers ; 10 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $4.4M 6 trades by 4 insiders, last 12 months Insider sales History → $47.5M 11 trades by 7 insiders · 0% under pre-set plans
Net ▼ $43.1M net selling
Insider Date Trade Shares Price Value
Mccoy John A. Jr. VICE PRESIDENT AND CONTROLLER September 2, 2026 Sell 27 $109.54 $2,958
Ford Robert B CHAIRMAN AND CEO August 25, 2026 Sell 180,297 $116.19 $20.9M
Ford Robert B CHAIRMAN AND CEO August 25, 2026 Sell 218,535 $115.57 $25.3M
Morrone Louis H. EXECUTIVE VICE PRESIDENT August 11, 2026 Sell 5,850 $109.83 $642,506
Stratton John G Director May 7, 2026 Buy 2,000 $86.82 $173,640
Starks Daniel J Director April 27, 2026 Buy 10,000 $92.65 $926,537
Boudreau Philip P EVP AND CFO April 23, 2026 Buy 2,200 $91.50 $201,300
Cushman Elizabeth C. EVP, GC AND SECRETARY March 2, 2026 Sell 263 $115.58 $30,398
Mccoy John A. Jr. VICE PRESIDENT AND CONTROLLER March 2, 2026 Sell 585 $115.58 $67,614
Moreland Mary K EXECUTIVE VICE PRESIDENT March 2, 2026 Sell 613 $115.58 $70,851
Morrone Louis H. EXECUTIVE VICE PRESIDENT March 2, 2026 Sell 1,144 $115.58 $132,224
Salvadori Daniel Gesua Sive EVP AND GROUP PRESIDENT March 2, 2026 Sell 885 $115.58 $102,288

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 132 trades and filings

In the last 12 months, 12 members of Congress disclosed 8 purchases and 17 sales of Abbott Laboratories shares.

  • Pete Sessions(R-TX 17):Sale (full), $50,001 - $100,000, traded October 2, 2026, filed October 27, 2026
  • Gilbert Ray Cisneros, Jr.(D-CA 31):Purchase, $1,001 - $15,000, traded September 18, 2026, filed October 12, 2026
  • Thomas H. Kean, Jr.(R-NJ 7):Sale (partial), $1,001 - $15,000, traded September 17, 2026, filed October 30, 2026

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around January 21, 2027 estimated from the company's past filing pattern, not announced

  • October 21, 2026
  • July 16, 2026
  • April 16, 2026
  • January 22, 2026
  • October 15, 2025
  • July 17, 2025

Recent SEC filings

Data status

When each part of this page on Abbott Laboratories was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Abbott Laboratories in brief

What does Abbott Laboratories do?
Abbott Laboratories is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Abbott Laboratories's stock ticker?
Abbott Laboratories trades under the ticker ABT on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Abbott Laboratories's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Abbott Laboratories reported revenue of $46.6B, 8.1% higher than a year earlier, according to its SEC filings.
What is Abbott Laboratories's free cash flow?
Abbott Laboratories's free-cash-flow margin is 16.8% of revenue over the trailing twelve months, ranking 17 of the 128 health care equipment companies we cover.
What is Abbott Laboratories's fair value (intrinsic value) per share?
Our discounted-cash-flow model of Abbott Laboratories's free cash flow after stock-based pay gives ~$73 per share in the base case, and ~$51–$100 across growth scenarios. These are model values under stated assumptions — not a price target or a recommendation.
Who are Abbott Laboratories's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Vanguard Capital Management LLC and State Street Corp. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Abbott Laboratories buying back stock, and does it pay a dividend?
Abbott Laboratories spent $1.8B on share repurchases over the trailing twelve months, and its diluted share count fell 0.1% over the year.
What is Abbott Laboratories's market cap?
On November 2, 2026, Abbott Laboratories's market capitalisation was about $192B, with a price-to-earnings ratio of 35.5 and net debt of $27.5B. Market figures come from third-party market data and may be delayed.
Does Abbott Laboratories pay a dividend?
Yes: Abbott Laboratories paid $4.3B in dividends over the trailing twelve months, a dividend yield of 2.22% and a payout ratio of 78.5%.
How much debt does Abbott Laboratories have?
Abbott Laboratories's debt-to-equity ratio is 63.8%, from its latest balance sheet (48.3% five years earlier). The financial health section below sets out its other solvency checks.
Who are Abbott Laboratories's competitors?
In our Health Care Equipment peer group, the companies closest to Abbott Laboratories are Medtronic, Stryker Corporation, GE HealthCare, Boston Scientific and Koninklijke Philips NV. The side-by-side comparison below sets their revenue, margins and growth against Abbott Laboratories's.
Are insiders buying or selling Abbott Laboratories stock?
Over the last 12 months, Abbott Laboratories's directors and officers reported 6 open-market purchases and 11 sales on Form 4. The insider trading page charts every trade.
When is Abbott Laboratories's next earnings date?
Around January 21, 2027, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Abbott Laboratories announces its own schedule.